Efficacy and safety of nebulized formoterol as add-on therapy in copd patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial

Drugs

Volumn 69, Issue 9, 2009, Pages 1205-1216

  Hanania, Nicola A ^a   Boota, Ahmad ^b   Kerwin, Edward ^c   Tomlinson, LaTanya ^d   Denis Mize, Kimberly ^e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Greenville Pharmaceutical Research   (United States)

^c Clinical Research Institute of Southern Oregon   (United States)

^d Formerly of Dey LP   (United States)

^e Dey Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMOTEROL; PERFOROMIST; PLACEBO; SALBUTAMOL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; AGED; ANGINA PECTORIS; ANXIETY; ARTICLE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; INSOMNIA; INSPIRATORY CAPACITY; IRRITABILITY; LUNG FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALAISE; MALE; METABOLIC ACIDOSIS; MORNING DOSAGE; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; NEBULIZER; QT PROLONGATION; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SPIROMETRY; TACHYCARDIA; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; XEROSTOMIA;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; AGED; ALBUTEROL; AREA UNDER CURVE; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; DYSPNEA; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SCOPOLAMINE DERIVATIVES; SPIROMETRY;

EID: 67649317017     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-200969090-00005     Document Type: Article

References (35)

1. Global initiative for chronic obstructive lung disease (GOLD): report of the GOLD workshop, global strategy for diagnosis, management and prevention of COPD. 2007 update [online]. Available fromURL: http://www.goldcopd. com [Accessed 2008 Nov 10]
2. Anderson GP, Linden A, Rabe KF. Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 1994; 7: 569-78
3. Reddy CB, Kanner RE. Is combination therapy with inhaled anticholinergics and beta2-adrenoceptor agonists justified for chronic obstructive pulmonary disease? Drugs Aging 2007; 24: 615-28
4. Tennant RC, Erin EM, Barnes PJ, et al. Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified? Curr Opin Pharmacol 2003; 3: 270-6
5. Keam SJ, Keating GM. Tiotropium bromide: a review of its use as maintenance therapy in patients with COPD. Treat Respir Med 2004; 3: 247-68
6. Takahashi T, Belvisi MG, Patel H, et al. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 1994; 150: 1640-5
7. Richter K, Stenglein S, Mucke M, et al. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration 2006; 73: 414-9
8. Jeffery PK, Venge P, Gizycki MJ, et al. Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. Eur Respir J 2002; 20: 1378-85
9. Johnson M, Rennard S. Alternative mechanisms for long-acting beta (2)-adrenergic agonists in COPD. Chest 2001; 120: 258-70
10. 2-agonists on pulmonary artery pressure in COPD patients. Pulmon Pharmacol Ther 2007; 20: 258-64
11. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125: 249-59
12. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasonesalmeterol for treatment of chronic obstructive pulmonary disease. Ann Int Med 2007; 146: 545-55
13. Cazzola M, Centanni S, Santus P, et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 2004; 98: 1214-21
14. Singh D, Brooks J, Hagan G, et al. Triple therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; 63: 592-8
15. Cazzola M, Santus P, Di Marco F, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004; 17: 35-9
16. Cazzola M, Noschese P, Salzillo A, et al. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med 2005; 99: 524-8
17. Tashkin DP, Pearle J, Iezzoni D, et al. Formoterol and tiotropium compared with tiotropium for COPD. COPD 2009; 6: 17-25
18. Terzano C, Petroianni A, Conti V, et al. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir Med 2008; 34: 255-62
19. van Noord JA, Aumann J-L, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 20: 214-22
20. van Noord JA, Aumann J-L, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129: 509-17
21. Vogelmeier C, Kardos P, Harari S, et al. Formoterol monoand combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008; 102: 1511-20
22. Gross NJ, Kerwin E, Levine B, et al. Nebulized formoterol fumarate: dose selection and pharmacokinetics. Pulm Pharmacol Ther 2008; 21: 818-23
23. Tashkin DP, Littner M, Andrews CP, et al. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 2008; 102: 479-87
24. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123: 659-64
25. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure for chronic airflow limitation: the St. George's respiratory questionnaire. Am Rev Respir Dis 1992; 145: 1321-7
26. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-8
27. Perforomist [package insert]. Napa (CA): Dey LP, 2007
28. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-24
29. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19: 209-16
30. Gross NJ, Nelson HS, Lapidus RJ, et al. Efficacy and safety of formoterol fumurate delivered by nebulization to COPD patients. Respir Med 2008; 102: 189-97
31. Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol; dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778-84
32. Rossi A, Kristufek P, Levine B, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121: 1058-69
33. Baumgartner RA, Hanania NA, Calhoun WJ, et al. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther 2007; 29: 261-78
34. Hanrahan JP, Hanania NA, Calhoun WJ, et al. Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD 2008; 5: 25-34
35. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002; 19: 398-404